GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Other Current Assets

ImmunityBio (FRA:26CA) Other Current Assets : €23.35 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Other Current Assets?

ImmunityBio's other current assets for the quarter that ended in Sep. 2024 was €23.35 Mil.

ImmunityBio's quarterly other current assets declined from Mar. 2024 (€21.24 Mil) to Jun. 2024 (€19.49 Mil) but then increased from Jun. 2024 (€19.49 Mil) to Sep. 2024 (€23.35Mil).

ImmunityBio's annual other current assets increased from Dec. 2021 (€14.07 Mil) to Dec. 2022 (€29.74 Mil) declined from Dec. 2022 (€29.74 Mil) to Dec. 2023 (€22.42 Mil).


ImmunityBio Other Current Assets Historical Data

The historical data trend for ImmunityBio's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Other Current Assets Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
- 11.22 14.07 29.74 22.42

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.51 22.42 21.24 19.49 23.35

ImmunityBio Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


ImmunityBio Other Current Assets Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

ImmunityBio Headlines

No Headlines